TY - CHAP M1 - Book, Section TI - Drug Development, Adverse Drug Events, and Postmarketing Surveillance A1 - Cantilena, Louis R. A2 - Hoffman, Robert S. A2 - Howland, Mary Ann A2 - Lewin, Neal A. A2 - Nelson, Lewis S. A2 - Goldfrank, Lewis R. PY - 2015 T2 - Goldfrank's Toxicologic Emergencies, 10e AB - This chapter will focus on drug-induced diseases that occur as expected or unexpected adverse drug events (ADEs), as a drug–drug interaction or an ADE causing an untoward drug–disease interaction. Also included in this chapter is a discussion of an approach to the diagnosis of drug-induced disease, an overview of the new drug approval process in the United States, monitoring of drug safety postapproval, and the suggested role for the ­medical toxicologist in the discovery, reporting, and prevention of ADEs. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessemergencymedicine.mhmedical.com/content.aspx?aid=1108438511 ER -